M1 Kliniken AG Reports Strong Financial Growth in First Nine Months of 2025, Driven by Beauty Segment Performance
TL;DR
M1 Kliniken AG's strategic sale of HAEMATO Pharm and focus on medical aesthetics positions investors for advantage with 11% EBIT growth and expanding market leadership.
M1 Kliniken achieved profitability through efficiency measures, capacity expansion, and optimized processes, resulting in 6.7% revenue growth and improved EBIT margins across segments.
M1 Kliniken's expansion of medical aesthetic services provides accessible, physician-performed treatments at leading prices, improving patient access to quality care globally.
M1 Kliniken operates 58 clinics across ten countries and aims to become the world's leading aesthetic medicine brand by 2029 through strategic vertical integration.
Found this article helpful?
Share it with your network and spread the knowledge!
M1 Kliniken AG reported substantial financial growth for the first nine months of 2025, with EBIT increasing by 11% to EUR 24.5 million compared to EUR 22.1 million in the same period last year. The company achieved earnings per share of EUR 0.86, up from EUR 0.77 in the previous year, while group revenue grew by 6.7% to EUR 274.3 million from EUR 257.2 million in the first nine months of 2024. The Beauty segment emerged as the primary growth driver, showing particularly strong performance with revenue increasing by 9.5% to EUR 77.8 million and EBIT surging by 29.7% to EUR 21.1 million.
The segment's EBIT margin improved significantly to 27.1% from 22.9% in the previous year, reflecting successful efficiency gains through optimized processes and higher utilization of medical capacities. The company's targeted pricing strategy aimed at attracting new customer groups supported market share expansion without compromising margin quality. Meanwhile, the Trading segment recorded solid revenue growth of 6% to EUR 196.5 million, though EBIT declined by 41.4% to EUR 3.4 million compared to the previous year's EUR 5.8 million. The company's overall EBIT margin improved to 8.9% from 8.6% in the same period last year, while EBITDA increased by 9% to EUR 28.2 million from EUR 25.9 million in the first nine months of 2024.
M1 Kliniken AG announced that its 85% subsidiary, HAEMATO AG, has signed an agreement to sell its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe's leading healthcare providers based in Mannheim. This transaction, subject to usual antitrust approvals, represents a strategic move to position the company as the world's leading vertically integrated pure-play provider of medical aesthetics. The company's outlook remains positive, with plans to continue its profitable growth trajectory by expanding its network of national and international clinics.
By 2029, the company expects to achieve revenue between EUR 200 million and EUR 300 million with a sustainable EBIT margin of at least 20%. The Group is consistently pursuing the goal of establishing M1 Med Beauty as the world's leading brand for aesthetic medicine, building on its current position as the leading fully integrated provider of medical aesthetic services in Europe and Australia. Additional information about the company's performance and strategic direction can be found at https://www.m1-kliniken.de.
Curated from NewMediaWire
